전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved82 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTLimited DatastaleTessa TherapeuticsPhase 1

CD30 CAR-T (CD30 CAR-T)

Anaplastic Large Cell Lymphoma; Peripheral T Cell Lymphoma · CD30

#CD30#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleMiltenyi Biotec B.V. & Co. KGPhase 2

CD318-CAR-T cells (CD318-CAR-T cells)

Carcinoma, Pancreatic Ductal; Pancreatic Neoplasms · CD3

#CD3#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleZhejiang UniversityPhase 1

CD33 CAR T-cells (CD33 CAR T-cells)

Acute Myeloid Leukemia · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleZhejiang UniversityPhase 1

CD33 CAR-T (CD33 CAR-T)

AML · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleHangzhou Qihan Biotech Co., Ltd.Phase 1

CD33/CLL1 dual CAR-NK cell (CD33/CLL1 dual CAR-NK cell)

AML, Adult; Minimal Residual Disease · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited DatastaleCenter for International Blood …Phase 2

CD33CART allogeneic (CD33CART allogeneic)

Acute Myelogenous Leukemia · CD33

#CD33#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleCenter for International Blood …Phase 2

CD33CART autologous (CD33CART autologous)

Acute Myelogenous Leukemia · CD33

#CD33#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleUniversity of PennsylvaniaPhase 1

CD33KO-HSPC; CART33 (CD33KO-HSPC; CART33)

Leukemia, Myeloid, Acute · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleNational Institute of Allergy a…Phase 2

CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1α-hγc-OPT (CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1α-hγc-OPT)

X-Linked Combined Immunodeficiency Diseases · CD3

#CD3#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 2

CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells (CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells)

Acute Myeloid Leukemia · CD33

#CD33#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 1

CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells (CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells)

Acute Myeloid Leukemia · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleGuangzhou Bio-gene Technology C…Preclinical

CLL1+CD33 CAR-T (CLL1+CD33 CAR-T)

Acute Myeloid Leukemia · CD33

#CD33#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleiCell Gene TherapeuticsPhase 1

CLL1-CD33 cCAR T cells (CLL1-CD33 cCAR T cells)

Hematologic Malignancy; Acute Myeloid Leukemia · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleGerman Cancer Research CenterPhase 1

Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion (Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion)

Relapsed/Refractory Acute Myeloid Leukemia (AML) · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing Boren HospitalPhase 1

Dual CD33/CLL1 CAR T (Dual CD33/CLL1 CAR T)

Acute Myeloid Leukemia · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleChinese PLA General HospitalPhase 2

Dual Specificity CD38 and bcma CAR-T Cells (Dual Specificity CD38 and bcma CAR-T Cells)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 2

Infusion of 4SCAR-T specific to CD22/CD123/CD38/ CD10/CD20 (Infusion of 4SCAR-T specific to CD22/CD123/CD38/ CD10/CD20)

CD19 Negative B-cell Malignancies · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleNationwide Children's HospitalPhase 2

Universal donor derived CD33 CAR-NK (Universal donor derived CD33 CAR-NK)

Relapsed/Refractory AML · CD33

#CD33#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleShanghai First Song Biotechnolo…Phase 1

anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells (anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells)

Relapsed/refractory Lymphoma; Relapsed/Refractory Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleChinese PLA General HospitalPhase 2

anti-CD33 CART (anti-CD33 CART)

Relapsed Adult Myeloid Leukemia; Chemotherapy Refractory Adult Myeloid Leukemia · CD33

#CD33#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active

4 / 5 pages

← PreviousNext →